Navigation Links
Study reveals that financial conflicts of interest are associated with positive study outcomes
Date:5/27/2011

Results demonstrate that 91% of RCTs recording this kind of FCOI achieved a positive - outcome, compared to 66.7% of RCTs without specific FCOI (p=0.02) and adjusting for confounding factors did not change this finding.

Results of this American study demonstrate that between the two periods 2002-3 and 2006-7 there was a significant increase in the number of RA RCTs listing lead authors as receiving consulting fees/honoraria (14.6% in the first time period compared to 40% in the second (p=0.004)). FCOIs including research grants, employment by sponsoring pharmaceutical company and share ownership were disclosed by at least one author in 53.4% of the 103 eligible RCTs studied. It could be possible that the difference noted between the two periods simply reflects a natural increase in the number of authors proactively reporting conflicts of interest.

"The number of pharmaceutical treatment options for RA has increased remarkably in recent years, partly as a result of increased funding from pharmaceutical companies," said Dr. Khan an Assistant Professor from the Division of Rheumatology at the University of Arkansas for Medical Sciences, USA. "Our study has shown that certain FCOIs among study authors have an increased likelihood of positive outcomes favouring the sponsor‟s drug. There are many potential reasons for these results it could be possible that more experienced clinicians hired by industry have a greater likelihood of achieving positive results because of superior trial design or that positive trials results are more likely to be published than negative ones."

FCOIs were disclosed by at least one author in 55 of the 103 (53.4%) eligible RCTs assessed by the study authors. Forty nine (47.6%) were employed by the industry sponsor, 29 (28.2%) had received consulting fees/honoraria, 14 (13.6%) had received research grants, and 13 (12.6%) owned shares in the pharmaceutical company. However, study authors found the correlation
'/>"/>

Contact: Rory Berrie
rory.berrie@cohnwolfe.com
44-790-151-3297
European League Against Rheumatism
Source:Eurekalert

Page: 1 2

Related biology news :

1. TGen study identifies compounds that could slow down Alzheimers disease
2. Study finds 2 gene classes linked to new prion formation
3. New study suggests link between chronic estrogen exposure and high blood pressure
4. Study confirms link between rheumatoid arthritis and COPD
5. Study shows the HPV vaccine Gardasil doesnt increase disease activity in SLE patients
6. Study reveals most biologically rich island in Southern Ocean
7. Study details path to sustainable aviation biofuels industry in Northwest
8. Global warming may affect the capacity of trees to store carbon, MBL study finds
9. New study provides global analysis of seagrass extinction risk
10. Baylor study finds common fire retardant harmful to aquatic life
11. Happy guys finish last, says new study on sexual attractiveness
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2014)... (Maximizing Access to Research Careers) Program has announced the ... Genetics from October 18 22, 2014 in San ... the entry of students, post doctorates and scientists from ... community and to encourage the participation of young scientists ... year MARC conferred 16 awards totaling $29,600., The FASEB ...
(Date:8/28/2014)... peer groups and clinicians is critical to the ... University of Georgia research. , A qualitative study ... determined that role models for successful breastfeeding help ... , "Mothers who received that support are more ... co-author Alex Anderson, an associate professor in the ...
(Date:8/28/2014)... to Research Careers) Program has announced the travel ... Medicine,s Conference on Integrative Physiology of Exercise from ... awards are meant to promote the entry of ... into the mainstream of the basic science community ... at the American College of Sports Medicine,s Conference ...
Breaking Biology News(10 mins):Breastfeeding study shows need for effective peer counseling programs 2
... conditions leading to heart attacks and strokes are treated ... or lung, but now turn out to involve some ... This in turn provides clues to more effective therapies ... in these distinct fields to come together. The seeds ...
... DC Although Americans are becoming increasingly aware of ... A in some baby bottles and lead in some ... with personal chemical exposure and related adverse health effects, ... Journal of Health and Social Behavior . ...
... the Nov. 20 edition of Heredity could ... evolution of separate sexes, a theory that holds that ... stages are not completely understood because the majority of ... state too long ago for scientists to observe the ...
Cached Biology News:Mechanisms of cardiovascular disease and cancer give clues to new therapies 2Mechanisms of cardiovascular disease and cancer give clues to new therapies 3Pollution at home lurks unrecognized, instead attributed to large-scale environmental disasters 2Two from one: Pitt research maps out evolution of genders from hermaphroditic ancestors 2
(Date:8/28/2014)... NEW YORK , Aug. ... announces that a new market ... its catalogue: Whole ... (Systems, Kits (Library Preparation, Target ... Technology (Sequencing by Synthesis), by ...
(Date:8/28/2014)... 28, 2014  Armetheon, Inc. ( www.armetheon.com ), ... to late-stage cardiovascular drug candidates, today announced that ... round of financing. The Series A round was ... with participation from investors that included Atheneos Capital ... Larry Hsu , the founder of Impax ...
(Date:8/28/2014)... PrimeSource Building Products, Inc., a ... SoundConnect to support their communication needs with ... web conferencing platform GlobalMeet powered by SoundConnect. The ... SoundConnect delivers award winning “results driven” business ... will be utilizing GlobalMeet powered by SoundConnect ...
(Date:8/27/2014)... BOSTON , Aug. 27, 2014 Rhythm, ... diseases and genetic deficiencies that result in metabolic disorders, ... on Form S-1 with the U.S. Securities and Exchange ... of shares of its common stock. The number of ... the offering have not yet been determined. ...
Breaking Biology Technology:Whole Exome Sequencing Market by Product (Systems, Kits (Library Preparation, Target Enrichment), by Services (Sequencing), by Technology (Sequencing by Synthesis), by Application (Cancer, Monogenic disorders) - Global Forecast to 2018 2Whole Exome Sequencing Market by Product (Systems, Kits (Library Preparation, Target Enrichment), by Services (Sequencing), by Technology (Sequencing by Synthesis), by Application (Cancer, Monogenic disorders) - Global Forecast to 2018 3Whole Exome Sequencing Market by Product (Systems, Kits (Library Preparation, Target Enrichment), by Services (Sequencing), by Technology (Sequencing by Synthesis), by Application (Cancer, Monogenic disorders) - Global Forecast to 2018 4Whole Exome Sequencing Market by Product (Systems, Kits (Library Preparation, Target Enrichment), by Services (Sequencing), by Technology (Sequencing by Synthesis), by Application (Cancer, Monogenic disorders) - Global Forecast to 2018 5Whole Exome Sequencing Market by Product (Systems, Kits (Library Preparation, Target Enrichment), by Services (Sequencing), by Technology (Sequencing by Synthesis), by Application (Cancer, Monogenic disorders) - Global Forecast to 2018 6Whole Exome Sequencing Market by Product (Systems, Kits (Library Preparation, Target Enrichment), by Services (Sequencing), by Technology (Sequencing by Synthesis), by Application (Cancer, Monogenic disorders) - Global Forecast to 2018 7Whole Exome Sequencing Market by Product (Systems, Kits (Library Preparation, Target Enrichment), by Services (Sequencing), by Technology (Sequencing by Synthesis), by Application (Cancer, Monogenic disorders) - Global Forecast to 2018 8Whole Exome Sequencing Market by Product (Systems, Kits (Library Preparation, Target Enrichment), by Services (Sequencing), by Technology (Sequencing by Synthesis), by Application (Cancer, Monogenic disorders) - Global Forecast to 2018 9Whole Exome Sequencing Market by Product (Systems, Kits (Library Preparation, Target Enrichment), by Services (Sequencing), by Technology (Sequencing by Synthesis), by Application (Cancer, Monogenic disorders) - Global Forecast to 2018 10Whole Exome Sequencing Market by Product (Systems, Kits (Library Preparation, Target Enrichment), by Services (Sequencing), by Technology (Sequencing by Synthesis), by Application (Cancer, Monogenic disorders) - Global Forecast to 2018 11Whole Exome Sequencing Market by Product (Systems, Kits (Library Preparation, Target Enrichment), by Services (Sequencing), by Technology (Sequencing by Synthesis), by Application (Cancer, Monogenic disorders) - Global Forecast to 2018 12Whole Exome Sequencing Market by Product (Systems, Kits (Library Preparation, Target Enrichment), by Services (Sequencing), by Technology (Sequencing by Synthesis), by Application (Cancer, Monogenic disorders) - Global Forecast to 2018 13Armetheon Completes $7.0 Million Series A Financing 2Armetheon Completes $7.0 Million Series A Financing 3PrimeSource Chooses SoundConnect as Collaboration Provider 2Rhythm Files Registration Statement for Proposed Initial Public Offering 2
... , , Additions to the Human Protein ... 6,100 antibodies powered by Atlas Antibodies , , ST. ... today announced the release of over 2,300 antibody additions to ... www.sigma.com/prestige ), bringing the total number of highly ...
... Austria, June 23 MIG Fonds and AFFiRiS AG are,this ... Award,competition, hosted by the industry magazine Boerse-Express and Junge,Industrie. The ... the Austrian biotechnology company as well as a euro,430 million ... Last Tuesday MIG Fonds and AFFiRiS AG were awarded ...
... June 22 Trubion Pharmaceuticals, Inc. (Nasdaq: ... of Wyeth (NYSE: WYE ), has exercised ... with Trubion to extend the research period for an ... terms of the research period extension, Wyeth,s obligations to ...
Cached Biology Technology:Sigma-Aldrich and Atlas Antibodies Announce 2,300 New, Highly Validated Prestige Antibodies(RM) 2Sigma-Aldrich and Atlas Antibodies Announce 2,300 New, Highly Validated Prestige Antibodies(RM) 3Sigma-Aldrich and Atlas Antibodies Announce 2,300 New, Highly Validated Prestige Antibodies(RM) 4AFFiRiS AG: 1st Place in Venture Capital & Private Equity Awards for MIG Fonds and AFFiRiS 2AFFiRiS AG: 1st Place in Venture Capital & Private Equity Awards for MIG Fonds and AFFiRiS 3Trubion Pharmaceuticals Announces Extension of Research Period Under Its Wyeth Collaboration 2Trubion Pharmaceuticals Announces Extension of Research Period Under Its Wyeth Collaboration 3
Rabbit polyclonal to CAMK 1D beta ( Abpromise for all tested applications). entrezGeneID: 57118 SwissProtID: Q5SQQ7...
Request Info...
Goat polyclonal to HNF4 ( Abpromise for all tested applications). Antigen: Synthetic peptide: RLSKTLVDMDMADY (Human) N terminal. Entrez GeneID: 3172 Swiss Protein ID: P41235...
Goat polyclonal to SART1 ( Abpromise for all tested applications). Antigen: Synthetic peptide: GSSKKHRGEKEAA, corresponding to N terminal amino acids 2-14 of Human SART1. Entrez Gene ID: 909...
Biology Products: